Aktienanalyse zu Danaher Corp (DHR)DHRDanaher Corp

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Danaher Corp is a good buy right now due to its strong Q3 performance, with total sales reaching $6.55 billion, an 8% year-over-year increase, and a net income surge of 36% to over $1.2 billion. Additionally, the stock's current price of $230.5 is below several analyst price targets, indicating potential upside. The main risk is the high forward P/E ratio of 23.81, which suggests that the stock may be overvalued if growth does not meet expectations.

17 analysts cover DHR: 13 rate it Buy, 4 Hold and 0 Sell. The average price target is 266.18.